NYSE American · Drug Manufacturers - General · USD
Nasus Pharma Ltd. (NSRX) Stock Analysis
Nasus Pharma Ltd. (NSRX) is a Drug Manufacturers - General stock listed on NYSE American and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
NSRX Key Statistics
As of Oct 21, 2026Trading
- Open
- $3.20
- Previous Close
- $3.24
- Day's Range
- 3.03–3.60
- 52-Week Range
- 1.98–9.50
- Volume
- 43.88K
Valuation
- Market Cap
- $35.84M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −1.20
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$5.86M
- Shares Outstanding
- 11.71M
- 1-Year Return
- −59.22%
Dividend and dates
- Avg Volume
- 16.87K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, NSRX closed at $3.06, −59.22% over 1 year.
Nasus Pharma Ltd. (NSRX) has a market capitalization of $35.84M.
In fiscal 2025, NSRX reported revenue of $0.00.
NSRX Stock Return by Calendar Year
Nasus Pharma Ltd. (NSRX) return since Aug 2025: what $10,000 became
- 1 year
- $10,000 $4,078
- −59.22%
- Since Aug 2025
- $10,000 $3,709
- −62.91%
If you had invested $10,000 in Nasus Pharma Ltd. (NSRX) at the close on August 13, 2025, the earliest close on record here, it would have been worth $3,709 at the close on October 21, 2026: −62.91% in total, −56.60% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −66.56% |
| 2025 (partial year) | +10.91% |
As of October 21, 2026.
NSRX Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$5.86M | — |
| 2024 | $0.00 | −$1.53M | — |
| 2023 | $0.00 | −$1.05M | — |
| 2022 | $0.00 | −$1.71M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$4.90M | −$5.86M | — |
| 2024 | $0.00 | — | −$1.08M | −$1.53M | — |
| 2023 | $0.00 | — | −$1.15M | −$1.05M | — |
| 2022 | $0.00 | — | −$2.04M | −$1.71M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of Ondansetron
YahooNasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis
YahooNasus Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
YahooNasus Pharma H1 EPS $(0.54) Misses $(0.20) Estimate
BenzingaNasus Pharma Appoints Brendan O'Grady As CEO, Succeeding Dan Teleman, Effective July 27
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Drug Manufacturers - General Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
MRKMerck & Co., Inc.
$369.78B
NVSNovartis AG
$292.58B
AZNAstraZeneca PLC
$261.82B
Popular Healthcare Stocks
UnitedHealth Group Incorporated
$374.30B
TMOThermo Fisher Scientific Inc.
$256.61B
AMGNAmgen Inc.
$236.98B
GILDGilead Sciences, Inc.
$190.42B
ABTAbbott Laboratories
$173.92B